Full-Time

Senior Data Scientist

Posted on 5/30/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

No salary listed

Hyderabad, Telangana, India

In Person

Category
Data & Analytics (1)
Required Skills
Power BI
Python
SAS
Machine Learning
Data Engineering
Tableau
Data Analysis
Requirements
  • Master’s / Bachelor’s degree in Data Science, Statistics, Computer Science, Biomedical Engineering, or a related field and 8 to 12 years of experience with one or more analytic software tools or languages (e.g., SAS, SPSS, Python) and experience with data visualization tools like Square Two (S2), Spotfire, BioConnect, Tableau, Power BI, Smartsheet, or similar
Responsibilities
  • Collect, clean, and run large datasets related to product performance and patient complaints.
  • Ensure data integrity, accuracy, and accessibility for further analysis.
  • Develop and maintain databases and data systems for storing patient complaints and product feedback.
  • Analyze data to identify patterns, trends, and correlations in patient complaints and product issues.
  • Use advanced statistical methods and machine learning techniques to uncover insights and root causes.
  • Develop analytics or predictive models to foresee potential product issues and patient concerns to address customer needs and opportunities.
  • Prepare comprehensive reports and visualizations to communicate findings to collaborators.
  • Present insights and recommendations to multi-functional teams, including product development, quality assurance, and customer service.
  • Collaborate with regulatory and compliance teams to ensure consistency to healthcare standards and regulations.
  • See opportunities for product enhancements and process improvements based on data analysis.
  • Work with product complaint teams to implement changes and monitor their impact.
  • Stay abreast of industry trends, emerging technologies, and standard methodologies in data science and healthcare analytics.
  • Evaluate data to support product complaints.
  • Work alongside software developers and software engineers to translate algorithms into commercially viable products and services.
  • Work in technical teams in development, deployment, and application of applied analytics, predictive analytics, and prescriptive analytics.
  • Perform exploratory and targeted data analyses using descriptive statistics and other methods.
  • Work with data engineers on data quality assessment, data cleansing and data analytics
  • Generate reports, annotated code, and other projects artifacts to document, archive, and communicate your work and outcomes.
Desired Qualifications
  • Demonstrated skill in the use of applied analytics, descriptive statistics, feature extraction and predictive analytics on industrial datasets.
  • Experience in statistical techniques and hypothesis testing, experience with regression analysis, clustering and classification.
  • Experience in analyzing time-series data for forecasting and trend analysis.
  • Experience with Data Bricks platform for data analytics.
  • Experience working with healthcare data, including patient complaints, product feedback, and regulatory requirements.
  • Any Python, SA, Salesforce or SQL certification (preferred)
  • Fluency in verbal and written English to be able to understand & articulate technical concepts

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Tarlatamab's China approval opens a new oncology market exceeding $2 billion annually.
  • Amgen invested nearly $2 billion in U.S. manufacturing over twelve months.
  • Q1 2026 free cash flow reached $1.5 billion, funding R&D and returns.

What critics are saying

  • Tavneos faces FDA withdrawal pressure after 76 liver-injury cases and eight deaths.
  • Prolia sales fell 34%, exposing Amgen's dependence on aging cash generators.
  • MariTide remains Phase 3 only, while Eli Lilly dominates the obesity market.

What makes Amgen unique

  • Amgen sells 17 products annualizing above $1 billion after Q1 2026.
  • Repatha grew 34% to $876 million, offsetting Prolia's sharp decline.
  • Thomas Dittrich returns September 2026 after CFO roles at Galderma and Shire.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Amgen who can refer or advise you

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Apr 3rd, 2026
Amgen faces Tavneos liver injury warning as Zai Lab oncology collaboration expands IMDELLTRA pipeline

Amgen faces fresh safety concerns after the FDA warned of severe liver injuries, including vanishing bile duct syndrome, linked to Tavneos (avacopan) in late March 2026. The development adds regulatory risk to the company's investment profile. Separately, Zai Lab announced a global collaboration with Amgen to test its DLL3-targeting ADC alongside Amgen's IMDELLTRA in extensive-stage small cell lung cancer, underscoring the company's ongoing oncology expansion through external partnerships. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. However, pessimistic analysts model revenues slipping to $34.4 billion with earnings near $5.2 billion, reflecting concerns around pricing pressure, biosimilar competition and rising research and development spend alongside the new safety issues.

Yahoo Finance
Mar 30th, 2026
Amgen stock up 24% since Jim Cramer's June recommendation, beats earnings estimates

Amgen, one of the world's largest pharmaceutical companies, has seen its shares rise 24% since Jim Cramer discussed the stock on Mad Money in June 2025. The company is currently developing the weight loss drug MariTide. Amgen's shares jumped 7.5% in November 2025 after posting third-quarter results that beat analyst expectations, with $9.6 billion in revenue and $5.64 earnings per share against forecasts of $8.98 billion and $5.04 respectively. In February 2026, shares rose 8% following fourth-quarter earnings that also exceeded estimates. Cramer expressed cautious optimism about the biotech company, noting its mid-single-digit earnings growth and potential upside from its GLP-1 drug development. Whilst calling Eli Lilly his preferred GLP-1 play, Cramer said investors "could do a lot worse than Amgen" for a bargain option.

Yahoo Finance
Mar 25th, 2026
Wells Fargo lifts Amgen price target to $390, cites $20B myasthenia gravis market potential by 2036

Wells Fargo has raised its price target on Amgen to $390 from $375, maintaining an Equal Weight rating. The firm cited emerging therapies including CD20, BAFF/APRIL and next-generation complement inhibitors as potential drivers that could expand the generalized myasthenia gravis market threefold over the next decade, potentially reaching $15 billion in US sales and $20 billion globally by 2036. Separately, Jefferies initiated coverage on Amgen with a Hold rating and $350 price target on 10 March, noting the stock has gained approximately 35% over the past six months. Last month, Amgen reported fourth-quarter adjusted earnings per share of $5.29, beating the $4.76 consensus estimate, on revenue of $9.9 billion versus $9.45 billion expected.

Yahoo Finance
Mar 15th, 2026
Amgen joins TrumpRx discount scheme and lifts dividend to $2.52 per share

Amgen has announced a $2.52 per-share second-quarter dividend and joined the government-run TrumpRx platform to offer discounted drugs including Amjevita, Aimovig and Repatha. The company is also preparing for its 11 March presentation at the Leerink Global Healthcare Conference in Miami. The moves come alongside double-digit revenue and earnings per share growth in 2025 and advances in obesity and oncology programmes. However, the TrumpRx discounting could pressure net pricing as Amgen invests heavily in late-stage trials and manufacturing expansion. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. Some analysts see a tougher outlook, with revenue potentially drifting towards $34.4 billion and earnings around $5.2 billion.